Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure

被引：40

作者：

Askevold E.T. ^{[1
,2
,4
]}

Gullestad L. ^{[1
,2
,4
,6
]}

Dahl C.P. ^{[1
,2
,4
]}

Yndestad A. ^{[1
,4
,5
,6
]}

Ueland T. ^{[1
,6
]}

Aukrust P. ^{[1
,3
,5
,6
]}

机构：

[1] Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[2] Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[3] Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[4] K.G. Jebsen Cardiac Research Centre, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[5] K.G. Jebsen Inflammation Research Centre, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[6] Aukrust Faculty of Medicine, Oslo University Hospital, Rikshospitalet, 0424 Oslo

来源：

Current Heart Failure Reports | 2014年 / 11卷 / 2期

关键词：

Cytokine; Heart failure; Inflammation; Interleukin-6; Risk prediction; Sgp130; Therapy;

D O I：

10.1007/s11897-014-0185-9

中图分类号：

学科分类号：

摘要：

Both experimental and clinical evidence accumulated over the last couple of decades has linked inflammatory activation to the initiation and progression of chronic heart failure (HF). Circulating levels of inflammatory mediators are associated with cardiac function and inform risk prediction in patients, but the effect of anti-inflammatory therapy in HF remains uncertain. Interleukin (IL)-6 type cytokines are central to the inflammatory response, and convey their signals through the ubiquitously expressed glycoprotein (gp) 130 receptor subunit. IL-6-type/gp130 signaling therefore represents an inflammatory nexus, with inherent potential for disease modification. This review focuses on the current knowledge of IL-6/gp130 signaling in relation to HF, with a particular emphasis on the role of soluble gp130 (sgp130), a signaling pathway modulator. Biological aspects of sgp130 and IL-6 signaling are discussed, as are potential novel therapeutic approaches to modulate this central inflammatory signaling pathway. © Springer Science+Business Media 2014.

引用

页码：146 / 155

页数：9

共 108 条

[1] Levine B., Kalman J., Mayer L., Fillit H.M., Packer M., Elevated circulating levels of tumor necrosis factor in severe chronic heart failure, New England Journal of Medicine, 323, 4, pp. 236-241, (1990)
[2] Mann D.L., Inflammatory mediators and the failing heart: Past, present, and the foreseeable future, Circulation Research, 91, 11, pp. 988-998, (2002)
[3] Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P., Systemic inflammation in heart failure - The whys and wherefores, Heart Failure Reviews, 11, 1, pp. 83-92, (2006)
[4] Aukrust P., Ueland T., Lien E., Bendtzen K., Muller F., Andreassen A.K., Nordoy I., Aass H., Espevik T., Simonsen S., Froland S.S., Gullestad L., Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, American Journal of Cardiology, 83, 3, pp. 376-382, (1999)
[5] Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L., Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST), Circulation, 103, 16, pp. 2055-2059, (2001)
[6] Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., Et al., Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 11, 2, pp. 119-129, (2009)
[7] Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L., Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD), Journal of the American College of Cardiology, 27, 5, pp. 1201-1206, (1996)
[8] Velagaleti R.S., Gona P., Larson M.G., Wang T.J., Levy D., Benjamin E.J., Et al., Multimarker approach for the prediction of heart failure incidence in the community, Circulation, 122, 17, pp. 1700-1706, (2010)
[9] Ky B., French B., Levy W.C., Sweitzer N.K., Fang J.C., Wu A.H., Et al., Multiple biomarkers for risk prediction in chronic heart failure, Circ Heart Fail, 5, 2, pp. 183-190, (2012)
[10] Braunwald E., Heart Failure, JACC Heart Fail, 1, 1, pp. 1-20, (2013)

← 1 2 3 4 5 6 7 8 9 10 →